Boston Scientific Corporation  

(Public, NYSE:BSX)   Watch this stock  
Find more results for BSX
-0.03 (-0.11%)
Real-time:   11:44AM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 27.54 - 27.81
52 week 19.67 - 28.51
Open 27.72
Vol / Avg. 1.70M/6.33M
Mkt cap 37.78B
P/E 88.07
Div/yield     -
EPS 0.31
Shares 1.37B
Beta 1.10
Inst. own 95%
Jul 27, 2017
Q2 2017 Boston Scientific Corp Earnings Release - 9:30AM EDT - Add to calendar
Jul 27, 2017
Q2 2017 Boston Scientific Corp Earnings Call - 8:00AM EDT - Add to calendar
Jun 27, 2017
Boston Scientific Corp Investor Day - Webcast
May 23, 2017
Boston Scientific Corp at UBS Global Healthcare Conference - Webcast
May 18, 2017
Boston Scientific Corp at Bank of America Merrill Lynch Healthcare Conference - Webcast
May 16, 2017
Boston Scientific Corp EUROPCR Investor Update - Webcast
May 11, 2017
Boston Scientific Corp Investor Update at HRS - Webcast
May 3, 2017
Boston Scientific Corp Annual Shareholders Meeting (Estimated)
Apr 27, 2017
Q1 2017 Boston Scientific Corp Earnings Release
Apr 27, 2017
Q1 2017 Boston Scientific Corp Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 13.43% 4.14%
Operating margin 16.85% 5.33%
EBITD margin - 26.04%
Return on average assets 6.46% 1.92%
Return on average equity 16.87% 5.32%
Employees 27,000 -
CDP Score - -


MARLBOROUGH, MA 01752-1234
United States - Map
+1-508-6834000 (Phone)
+1-508-6508923 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Officers and directors

Michael F. Mahoney Chairman of the Board, President, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
Daniel J. Brennan Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Timothy A. Pratt Chief Administrative Officer, Executive Vice President, General Counsel, Secretary
Age: 67
Bio & Compensation  - Reuters
Supratim Bose Executive Vice President; President, Asia-Pacific, Middle East and Africa
Age: 64
Bio & Compensation  - Reuters
Keith D. Dawkins M.D. Global Chief Medical Officer, Executive Vice President
Age: 66
Bio & Compensation  - Reuters
Joseph M. Fitzgerald Executive Vice President; President - Rhythm Management
Age: 53
Bio & Compensation  - Reuters
Edward F. Mackey Executive Vice President - Operations
Age: 54
Bio & Compensation  - Reuters
Ian T. Meredith AM Executive Vice President, Global Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Michael P. Phalen Executive Vice President; President - MedSurg
Age: 57
Bio & Compensation  - Reuters
Wendy Carruthers Senior Vice President - Human Resources
Age: 48
Bio & Compensation  - Reuters